Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative toxicity of long-term colchicine in hemodialysis vs CKD stages 3–5
TCTR20251021012Not yet recruiting
- Sponsor
- Theerachai Thammathiwat
- Start
- Nov 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of colchicine in end-stage kidney disease (ESKD) and chronic kidney disease (CKD) (2 arms), sponsored by Theerachai Thammathiwat. Primary endpoint: Non-inferiority in toxicity of long-term colchicine between hemodialysis and CKD stages 3–5 groups. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
end-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on TCTR20251021012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251021012.